C.R. Bard Beats Analyst Estimates on EPS
C.R. Bard (NYS: BCR) reported earnings on April 24. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), C.R. Bard met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share expanded.
Gross margins contracted, operating margins contracted, net margins grew.
C.R. Bard logged revenue of $730.0 million. The 14 analysts polled by S&P Capital IQ anticipated a top line of $732.7 million on the same basis. GAAP reported sales were 4.2% higher than the prior-year quarter's $700.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $1.61. The 19 earnings estimates compiled by S&P Capital IQ forecast $1.57 per share on the same basis. GAAP EPS of $1.60 for Q1 were 7.4% higher than the prior-year quarter's $1.49 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 61.7%, 50 basis points worse than the prior-year quarter. Operating margin was 27.4%, 20 basis points worse than the prior-year quarter. Net margin was 19.0%, 20 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $757.6 million. On the bottom line, the average EPS estimate is $1.65.
Next year's average estimate for revenue is $3.03 billion. The average EPS estimate is $6.66.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 263 members out of 275 rating the stock outperform, and 12 members rating it underperform. Among 95 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 92 give C.R. Bard a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on C.R. Bard is hold, with an average price target of $93.36.
The healthcare investing landscape is littered with also-rans and a few major winners. Is C.R. Bard the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add C.R. Bard to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.